Sensyne Health’s COVID-19 risk prediction algorithm gets UK regulatory approval

Sensyne Health, a clinical AI company, gets the green light in the UK for its COVID-19 risk prediction algorithm SYNE-COV

Sensyne Health has received regulatory approval for its COVID-19 prediction algorithm, SYNE-COV, for use in the UK. The machine learning algorithm analyses more than 60 variables in a patients’ digital health record in bid to predict the probability of adverse health effects of COVID-19 positive patients.
The product is the result of the joint efforts of Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust and is the first algorithm of its kind to have garnered regulatory approval for the UK.
SYNE-COV was developed using the SENSE clinical and operational algorithm engine. SYNEs are the clinical AI algorithms that SENSE creates by analysing patient digital health records in order to provide clarity on decision making for clinicians.
Sensyne Health contend that SYNE-COV will now be marketed across the UK, in particular to NHS Trusts in bid to aid in COVID-19 readiness and will be available for the 2021/2022 winter season.
Dominic Conlin, hospital director, Chelsea and Westminster Hospital NHS Foundation Trust, shared in a press release:

We’re excited by the possibilities this offers. This is individualised care by using patients’ own data to stratify risks and predict responses to clinical treatments, informing and supporting clinical decision making. This is a real step in taking forward digital innovation, data integration and analytics to enhance patient care in the NHS.

CEO of Sensyne Health, Lord Paul Drayson, added:

This is the first Sensyne Clinical AI algorithm to achieve regulatory approval that has been developed using our SENSE clinical AI platform. The SENSE engine is expected to be able to generate clinical algorithms across a range of medical conditions that will provide real-time clinical decision-making support. Achieving the first regulatory approval is an important milestone for the company and we look forward to being able to roll SYNE-COV out to the NHS.